Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Table 1 Clinical data of patients and details of LCAR-B38M therapy

ID	Gender	Age (years)	Subtype	FISH	Conditioning regimen	CAR⁺T (10⁶ /kg)	CRS onset^a	CRS grading	TNF-α pre^b (pg/mL)	TNF-α post^c (pg/mL)	Best response	PFS (months)
Patient 1	M	67	IgA κ	Negative	CTX	0.21	Day 7	1	17.64	204.22	sCR	6
Patient 2	M	63	IgA κ	NA	CTX	0.35	Day 9	1	12.36	130.98	NR	6
Patient 3	F	53	IgG κ	Gain(1q), del(13q), t(4; 14)	CTX	0.46	Day 9	1	12.58	13.69	sCR	18
Patient 4	M	56	IgA κ	Gain(1q), del(13q)	CTX	1.52	Day 8	3	4.27	1728.58	sCR	24
Patient 5	F	56	IgA κ	Negative	CTX	0.41	Day 9	1	< 2.5	< 2.5	sCR	33 +
Patient 6	F	64	IgG-κ	t (14; 16)	FC	0.73	Day 4	2	< 2.5	4.45	sCR	13 +
Patient 7	F	67	κ	Negative	FC	0.65	Day 7	1	< 2.5	< 2.5	CR	9 +
Patient 8	M	63	κ	Gain(1q), del(13q), t(11;14)	FC	0.50	Day 6	1	< 2.5	76.09	sCR	7 +

M male, F female, FISH fluorescence in situ hybridization, CTX cyclophosphamide 300 mg/m² daily for 3 day, FC cyclophosphamide 250 mg/m² daily and fludarabine 25 mg/m² daily for 3 days, NA not available, TNF tumor necrosis factor, PFS progression-free survival
^aThe starting day of LCAR-B38M CAR T-cell infusion was day 0
^bTNF-α pre refers to the levels of serum TNF-α before CAR T cell infusion
^cTNF-α post refers to the peak levels of serum TNF-α after CAR T cell infusion

ISSN: 2162-3619